11 National Cancer Center Hospital East, Kashiwa, Japan.10 The University of Texas MD Anderson Cancer Center, Houston, TX.9 Princess Margaret Cancer Center, Toronto, Ontario, Canada.8 Centre Oscar Lambret and Lille University, Lille, France.7 Meir Medical Center, Tel Aviv, Israel.6 Sourasky Medical Center, Tel Aviv, Israel.5 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.4 Center for Immuno-Oncology, University Hospital of Siena, Italy.3 Instituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy.2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.1 Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U1015, Villejuif, France.ORR, the durability of response, 12-month PFS, patient-reported quality of life, and safety are secondary goals. PFS per RECIST v1.1 (evaluated by blinded independent central review) and OS are the primary objectives. Treatment will last 35 cycles (two years) or until illness progression, intolerable toxicity, or patient withdrawal. Metastasis status at diagnosis, planned bevacizumab usage (yes/no), and tumor PD-L1 CPS (1, 1 to 10, or 10) will all be used to stratify patients. Before randomization, the investigator will choose the CT regimen (paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5, with or without bevacizumab 15 mg/kg). KEYNOTE-826 (NCT03635567) is a phase 3 randomized, double-blind, international trial evaluating the effectiveness and acceptability of CT in the first-line context with or without pembrolizumab and/or bevacizumab.Įvery three weeks, eligible patients with recurrent, persistent, or metastatic cervical cancer who have not previously had CT in a recurrent or metastatic context and are not susceptible to curative therapy will be randomized 1:1 to CT + pembrolizumab 200 mg or placebo. The PD-1 inhibitor pembrolizumab was granted accelerated approval by the US FDA for patients with PD-L1–positive (combined positive score of > 1) cervical cancer who had progressed during or after treatment based on an ORR of 14.3 percent (95 percent CI, 7.4-24.1) in the cervical cancer cohort of KEYNOTE-158 (Chung et al. 2017), VEGF has emerged as a therapeutic target for these patients. Although adding the anti-VEGF agent bevacizumab to platinum- and taxane-based chemotherapy (CT) is associated with a modest OS benefit compared to CT alone (median OS, 16.8 vs 13.3 mo hazard ratio, 0.77, 95 percent CI, 0.62-0.95 P = 0.007 Tewari et al. Patients with advanced cervical cancer have a significant chance of death and a poor prognosis. Intégrer (Iframe): Copier dans le presse-papier iFrame is not supported! Intégrer (Object): Copier dans le presse-papier Link (HTML): Copier dans le presse-papier Bradley Monk, MD #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826 Link (BBCode): Copier dans le presse-papier Bradley Monk, MD #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826īradley Monk, MD, FACOG, FACS, Gynecologic Oncologist, Arizona Oncology speaks about the ESMO 2021 Abstract #LBA2, Presidential Symposium: KEYNOTE-826: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. How To Self Record An Interview and Presentations Self Serve Advertising Portal - Buy Ads Now! No Contracts!
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |